Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:PD-L1 expression can be regarded as prognostic factor for survival of non-small cell lung cancer patients after chemoradiotherapy
Avtorji:ID Vrankar, Martina (Avtor)
ID Zwitter, Matjaž (Avtor)
ID Kern, Izidor, Klinika Golnik (Avtor)
ID Stanič, Karmen (Avtor)
Datoteke:URL URL - Izvorni URL, za dostop obiščite http://www.elis.sk/download_file.php?product_id=5518&session_id=kocugv6art3ltib4t6te7tjam3
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
Povzetek:The standard treatment for inoperable locally advanced non-small cell lung cancer (LA NSCLC) includes concurrent or sequential chemotherapy (ChT) and radiation therapy (RT). Long term survival rates with these approaches remains only in the order of 15%, therefore new treatment strategies, including immunotherapy, are under investigation, with programmed death ligand-1 (PD-L1) as one of the major players. We evaluated the clinical significance of PD-L1 expression in tumor samples from patients with inoperable LA NSCLC who underwent concurrent chemoradiotherapy (CRT) in our institution between 2005 and 2010 and correlated their expression with clinicopathological parameters and outcome of treatment. Among 107 patients treated with concurrent CRT, a total of 43 (36 males and 7 females) had sufficient tissue for immunohistochemical (IHC) staining. The expression of PD-L1 was demonstrated in 7 tumors, in 6 males and 1 female. No statistical significant differences in patient characteristics, including age, smoking status and gender, were found according to the PD-L1 expression. After a median follow up of 103.6 months, median progression free survival (PFS) was 19.9 months in patients without and 10.1 months in patients with PD-L1 expression (p=0.008). Median overall survival (OS) was 28.4 and 12.1 months for PD-L1 negative and PD-L1 positive patients, respectively (p=0.012). In conclusions, patients with PD-L1 expression had shorter PFS and OS after concurrent CRT in LA NSCLC. Unfortunately, only small number of patients had tissue available for the IHC testing, therefore no firm conclusions could be made and further investigation is warranted.
Ključne besede:non-small cell lung cancer, lung cancer, chemoradiotherapy, survival
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Kraj izida:Slovaška
Založnik:AEPress
Leto izida:2018
Št. strani:str. 140-146
Številčenje:Vol. 65, no. 1
PID:20.500.12556/DiRROS-12920 Novo okno
UDK:616.2
ISSN pri članku:0028-2685
DOI:10.4149/neo_2018_170206N77 Novo okno
COBISS.SI-ID:2806907 Novo okno
Datum objave v DiRROS:17.12.2020
Število ogledov:2346
Število prenosov:580
Metapodatki:XML DC-XML DC-RDF
:
VRANKAR, Martina, ZWITTER, Matjaž, KERN, Izidor in STANIČ, Karmen, 2018, PD-L1 expression can be regarded as prognostic factor for survival of non-small cell lung cancer patients after chemoradiotherapy. Neoplasma [na spletu]. 2018. Vol. 65, no. 1, p. 140–146. [Dostopano 23 marec 2025]. DOI 10.4149/neo_2018_170206N77. Pridobljeno s: http://www.elis.sk/download_file.php?product_id=5518&session_id=kocugv6art3ltib4t6te7tjam3
Kopiraj citat
  
Objavi na:Bookmark and Share


Iščem podobna dela...Prosim, počakajte...
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Neoplasma
Založnik:Cancer Research Institute of the Slovak Academy of Sciences
ISSN:0028-2685
COBISS.SI-ID:26004480 Novo okno

Sekundarni jezik

Jezik:Ni določen
Ključne besede:nedrobnocelični rak, pljučni rak, kemoradioterapija, preživetje


Nazaj